Endosomal ErbB Receptor and Src Signaling in Cancer

癌症中的内体 ErbB 受体和 Src 信号转导

基本信息

  • 批准号:
    7555313
  • 负责人:
  • 金额:
    $ 10万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): ErbB receptor tyrosine kinases play essential physiological roles in mediating cell proliferation, differentiation, survival, migration and differentiation during development and tissue homeostasis, and their overexpression and/or hyperactivity are directly linked to oncogenesis in a number of human cancers. ErbB receptor activation also initiates cytoprotective signaling that limits the extent of tumor killing by radiation and/or chemotherapy, and their inhibition represents an important strategy for radio- and chemo-sensitization of tumors. Elucidating novel aspects of ErbB receptor signaling is therefore a major goal in cancer biology. Ligand binding to ErbB receptors induces rapid intemalization into endosomes followed by a sorting process to target them to lysosomal degradation or for recycling. Rather unexpectedly, recent studies have shown that activated ErbB receptors continue to signal after their internalization. The nature of the signaling endosomal compartment(s), the specific signaling events that take place in endosomes, and the cellular mechanisms that regulate the delivery of activated ErbB receptors into these signaling compartments remain unknown. A number of experimental findings lead us to postulate a novel role for Src tyrosine kinase as a positive regulator and/or mediator of ErbB signaling within the endosomal compartment. To test our hypotheses, we will compare immortalized, non-tumorigenic human mammary epithelial cells (MECs) with their isogenic derivatives overexpressing EGFR or ErbB2 with or without Src, which models the co-overexpression of these tyrosine kinases in breast and other cancers. We will first establish that Src is a positive regulator of ErbB receptor signals and biological responses in MECs. We will then use two-color imaging and biochemical analyses to determine the colocalization of Src and ErbB2 within the endocytic pathway, and identify the specific compartment in which they reside. We will carry out analyses to assess if endosomal ErbB receptor-Src complexes signal and determine the nature of such signals and their biological consequences, using Src kinase inhibition and perturbations of transport within the endocytic compartments. Validation of our hypotheses will represent a major shift in the current paradigm of ErbB receptor signaling, and will provide novel biochemical insights into the role of Src overexpression together with ErbB receptors in breast and other epithelial cancers. Our studies may identify novel targets for therapeutic intervention relevant to ErbBand Src-overexpressing human cancers.
描述(由申请人提供):ErbB受体酪氨酸激酶在发育和组织稳态过程中介导细胞增殖、分化、存活、迁移和分化中发挥重要的生理作用,并且它们的过表达和/或过度活性与许多人类癌症中的肿瘤发生直接相关。ErbB受体激活还启动细胞保护信号传导,其限制通过放射和/或化学疗法杀死肿瘤的程度,并且它们的抑制代表肿瘤的放射和化学敏化的重要策略。因此,阐明ErbB受体信号转导的新方面是癌症生物学的主要目标。与ErbB受体结合的配体诱导快速内化到内体中,随后进行分选过程以使其靶向溶酶体降解或再循环。令人意外的是,最近的研究表明,激活的ErbB受体在内化后继续发出信号。信号传导内体隔室的性质、内体中发生的特定信号传导事件以及调节活化的ErbB受体递送到这些信号传导隔室中的细胞机制仍然未知。许多实验结果使我们假设Src酪氨酸激酶作为ErbB信号传导的正调节剂和/或介导剂在内体隔室中的新作用。 为了验证我们的假设,我们将比较永生化的非致瘤性人乳腺上皮细胞(MEC)与其过表达EGFR或ErbB 2(有或无Src)的同基因衍生物,其模拟了这些酪氨酸激酶在乳腺癌和其他癌症中的共过表达。我们将首先建立Src是一个积极的ErbB受体信号和生物反应的MEC调节器。然后,我们将使用双色成像和生化分析,以确定共定位的Src和ErbB 2内吞途径,并确定它们所在的特定隔室。我们将进行分析,以评估是否内体ErbB受体-Src复合物的信号,并确定这些信号的性质及其生物学后果,使用Src激酶抑制和内吞隔室内的运输扰动。验证我们的假设将代表ErbB受体信号传导的当前范式的重大转变,并将提供新的生化见解Src过表达与ErbB受体在乳腺癌和其他上皮癌中的作用。我们的研究可能会确定新的目标,为相关的ErbBand Src过表达的人类癌症的治疗干预。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hamid Band其他文献

Hamid Band的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hamid Band', 18)}}的其他基金

Molecular Control of EGF Receptor Down-Regulation
EGF 受体下调的分子控制
  • 批准号:
    7909311
  • 财政年份:
    2009
  • 资助金额:
    $ 10万
  • 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
  • 批准号:
    8079123
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
  • 批准号:
    7212882
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
  • 批准号:
    7560152
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
  • 批准号:
    7632179
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
  • 批准号:
    7821323
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
ErbB2 Downregulation Through HSP90 Inhibition
通过 HSP90 抑制下调 ErbB2
  • 批准号:
    7477767
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
Endosomal ErbB Receptor and Src Signaling in Cancer
癌症中的内体 ErbB 受体和 Src 信号转导
  • 批准号:
    6916571
  • 财政年份:
    2004
  • 资助金额:
    $ 10万
  • 项目类别:
Endosomal ErbB Receptor and Src Signaling in Cancer
癌症中的内体 ErbB 受体和 Src 信号转导
  • 批准号:
    7227540
  • 财政年份:
    2004
  • 资助金额:
    $ 10万
  • 项目类别:
Targeting Endocytic Recycling of EGF Receptor in Cancer
靶向癌症中 EGF 受体的内吞再循环
  • 批准号:
    8665526
  • 财政年份:
    2004
  • 资助金额:
    $ 10万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 10万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 10万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 10万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 10万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了